Assessment of [18F]MNI-1054 as a Marker for LSD1

Phase 0 Completed 4 enrolled Invicro

NaSingle-groupOpen-labelOther

Summary

The primary objective of this protocol is to evaluate \[18F\]MNI-1054 as a Lysine-specific histone demethylase 1A (LSD1) enzyme targeted radiopharmaceutical.

Timeline

Start: 2018-08-09
Primary completion: 2019-05-02
Completion: 2019-05-02

Publications

Matsuda S, Hattori Y, Kimura H. Drug discovery strategy for TAK-418, a specific inhibitor of LSD1 enzyme activity, as a novel therapy for autism. Adv Pharmacol. 2025;102:267-300. doi: 10.1016/bs.apha.2024.10.017. Epub 2024 Oct 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	[18F]MNI-1054	Diagnostic / imaging agent	—	—

Indications

No indication recorded.